Correlation Between Aerovate Therapeutics and Oncorus
Can any of the company-specific risk be diversified away by investing in both Aerovate Therapeutics and Oncorus at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Aerovate Therapeutics and Oncorus into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Aerovate Therapeutics and Oncorus, you can compare the effects of market volatilities on Aerovate Therapeutics and Oncorus and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Aerovate Therapeutics with a short position of Oncorus. Check out your portfolio center. Please also check ongoing floating volatility patterns of Aerovate Therapeutics and Oncorus.
Diversification Opportunities for Aerovate Therapeutics and Oncorus
-0.48 | Correlation Coefficient |
Very good diversification
The 3 months correlation between Aerovate and Oncorus is -0.48. Overlapping area represents the amount of risk that can be diversified away by holding Aerovate Therapeutics and Oncorus in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Oncorus and Aerovate Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Aerovate Therapeutics are associated (or correlated) with Oncorus. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Oncorus has no effect on the direction of Aerovate Therapeutics i.e., Aerovate Therapeutics and Oncorus go up and down completely randomly.
Pair Corralation between Aerovate Therapeutics and Oncorus
If you would invest 4.35 in Oncorus on September 23, 2024 and sell it today you would earn a total of 0.00 from holding Oncorus or generate 0.0% return on investment over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Against |
Strength | Very Weak |
Accuracy | 4.76% |
Values | Daily Returns |
Aerovate Therapeutics vs. Oncorus
Performance |
Timeline |
Aerovate Therapeutics |
Oncorus |
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Aerovate Therapeutics and Oncorus Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Aerovate Therapeutics and Oncorus
The main advantage of trading using opposite Aerovate Therapeutics and Oncorus positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Aerovate Therapeutics position performs unexpectedly, Oncorus can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Oncorus will offset losses from the drop in Oncorus' long position.Aerovate Therapeutics vs. Fate Therapeutics | Aerovate Therapeutics vs. Sana Biotechnology | Aerovate Therapeutics vs. Caribou Biosciences | Aerovate Therapeutics vs. Arcus Biosciences |
Oncorus vs. Apollomics Class A | Oncorus vs. Pyxis Oncology | Oncorus vs. Zura Bio Limited | Oncorus vs. Altamira Therapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Other Complementary Tools
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Bonds Directory Find actively traded corporate debentures issued by US companies |